Skip to main content
Top
Published in: Reactions Weekly 1/2023

01-12-2023 | Alemtuzumab | Case report

Alemtuzumab

Immune mediated thrombocytopenic purpura, warm antibody haemolytic anaemia and neutropenia: 5 case reports

Published in: Reactions Weekly | Issue 1/2023

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Sandgren S, et al. The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey. Frontiers in Neurology 14: 2023. Available from: URL: http://doi.org/10.3389/fneur.2023.1137665 Sandgren S, et al. The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey. Frontiers in Neurology 14: 2023. Available from: URL: http://​doi.​org/​10.​3389/​fneur.​2023.​1137665
Metadata
Title
Alemtuzumab
Immune mediated thrombocytopenic purpura, warm antibody haemolytic anaemia and neutropenia: 5 case reports
Publication date
01-12-2023
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2023
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-51334-6

Other articles of this Issue 1/2023

Reactions Weekly 1/2023 Go to the issue

Case report

Ascorbic acid

Case report

Multiple drugs

Case report

Tacrolimus

Case report

Eculizumab